Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
6.58
-0.11 (-1.64%)
Oct 10, 2025, 2:58 PM EDT - Market open
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Aquestive Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $10.71, which forecasts a 62.77% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $17.
Price Target: $10.71 (+62.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +82.37% | Oct 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +21.58% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +51.98% | Jun 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $15 → $7 | Buy | Initiates | $15 → $7 | +6.38% | Jun 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +51.98% | May 15, 2025 |
Financial Forecast
Revenue This Year
45.85M
from 57.56M
Decreased by -20.35%
Revenue Next Year
69.46M
from 45.85M
Increased by 51.50%
EPS This Year
-0.66
from -0.51
EPS Next Year
-0.61
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.4M | 80.9M | |||
| Avg | 45.8M | 69.5M | |||
| Low | 39.5M | 51.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.2% | 76.3% | |||
| Avg | -20.4% | 51.5% | |||
| Low | -31.3% | 11.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | -0.46 | |||
| Avg | -0.66 | -0.61 | |||
| Low | -0.70 | -0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.